FAKTOR OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time BOERSE MUENCHEN 15:46:49 2024-06-26 EDT | ||
| 11.7 EUR | +0.95% |
|
| Current month | +8.13% | ||
| 1 month | +7.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 11.7 | +0.95% |
| 24-06-25 | 11.59 | -1.45% |
| 24-06-24 | 11.76 | +1.64% |
| 24-06-21 | 11.57 | -0.26% |
| 24-06-20 | 11.6 | +2.11% |
Real-time BOERSE MUENCHEN
Last update June 26, 2024 at 03:46 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD33L1 |
| ISIN | DE000HD33L14 |
| Date issued | 2024-02-27 |
| Strike | 237 $ |
| Maturity | Unlimited |
| Parity | 19.38 : 1 |
| Emission price | 10.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.26 € |
|---|---|
| Lowest since issue | 8.03 € |
| Spread | 0.01 € |
| Spread % | 0.09% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474
USD
Average target price
465.5
USD
Spread / Average Target
-1.79%
- Stock Market
- Certificates
- Certificat
